The Zhitong Finance App learned that Yingpai Pharmaceutical-B (07630) opened more than 3% higher. As of press release, it had risen 3.55% to HK$10.78, with a turnover of HK$306,200.

According to the news, on October 23, Yingpai Pharmaceutical-B announced that the latest clinical data of its pipeline drugs Senapali (IMP4297), IMP1734 (also known as EIK1003), and IMP1707 (also known as EIK1004) were displayed on a poster at the 2026 European Society of Medical Oncology (ESMO) conference held in Madrid, Spain from October 23 to 27, 2026.

Dr. Choi Sui-hung, CEO of the company, said, “We are pleased that the latest clinical data on Senapalil and the two novel selective PARP1 inhibitors, IMP1734 and IMP1707 were presented at the 2026 ESMO Conference. These data are further proof that our synthetic lethal R&D pipeline is progressing steadily. Looking forward to the future, we will continue to promote differentiated and precise anti-cancer therapies, accelerate global clinical development of products, and deepen cooperation with Eikon Therapeutics to bring real clinical benefits to cancer patients around the world.”

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.